Is BIOTEC-F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6
Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BIOTEC-F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BIOTEC-F (THB8) is trading below our estimate of fair value (THB38.35)
Significantly Below Fair Value: BIOTEC-F is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIOTEC-F?
Key metric: As BIOTEC-F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for BIOTEC-F. This is calculated by dividing BIOTEC-F's market cap by their current
revenue.
What is BIOTEC-F's PS Ratio?
PS Ratio
0.2x
Sales
฿4.55b
Market Cap
฿763.34m
BIOTEC-F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue
0.3x
Enterprise Value/EBITDA
38.8x
PEG Ratio
n/a
Price to Sales Ratio vs Peers
How does BIOTEC-F's PS Ratio compare to its peers?
Price-To-Sales vs Industry: BIOTEC-F is good value based on its Price-To-Sales Ratio (0.2x) compared to the Asian Shipping industry average (1.5x).
Price to Sales Ratio vs Fair Ratio
What is BIOTEC-F's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
BIOTEC-F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
0.2x
Fair PS Ratio
n/a
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BIOTEC-F's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.